Datamonitor, June 2011, Pages: 40
opportunities and challenges in the field.
- Understand corporate strategies for the life-cycle management of HIV drugs in the seven major markets. Executive Summary
Strategic scoping and focus
Datamonitor
Infiniti Research Limited, Dec 2011, Pages: 31
Retroviral Therapy (HAART) is the most effective way to reduce the risk of blood-borne infections. New studies from British Columbia Centre for Excellence (BC-CfE) in HIV/AIDS, San Francisco, states that HAART
Infiniti Research Limited, Nov 2011, Pages: 31
Retroviral Therapy (HAART) is the most effective way to reduce the risk of blood-borne infections. New studies from British Columbia Centre for Excellence (BC-CfE) in HIV/AIDS, San Francisco, states that HAART
Decision Resources, Inc., June 2011
bought its way into the upper echelons of the vaccine marketplace by acquiring Wyeth in 2009. Why would a company like Pfizer be attracted to a potential acquiree’s vaccine assets? What other notable
Global Industry Analysts, Inc., Oct 2006, Pages: 699
Considerably for Herpes Antiviral Market II-25
STDs, a Major Concern the World Over II-25
Microbiocides, a New Way to Fight STD and HIV Infections II-26
Spread of HIV Infection Poses a Global Health Risk II
Espicom Business Intelligence Ltd, Feb 2010, Pages: 72
Gilead’s HIV product portfolio remains its strongest asset, generating 81.2 per cent of total company sales in 2008. Atripla and Truvada are expected have combined sales approaching US$5 billion
Global Industry Analysts, Inc., Oct 2011, Pages: 660
-
Gaining Momentum 17
“Time Constraints?” - Rapid Tests to the Rescue 17
Rapid HIV Tests: A New Age Diagnostic Weapon Against the
Killer Disease 18
Accuracy/Reliability of Home HIV Testing: A Bone
Business Insights, June 2010, Pages: 191
. Molecular diagnostics is also addressing the need for tests that monitor the therapeutic efficacy of pharmaceuticals. In this way, it has evolved into an important business opportunity for in-vitro
Axis Research Mind, Nov 2011, Pages: 342
The broad ‘life science' division has been witnessing a rapid growth and technological improvements varying from sector to sector since the past 3-5 years. Accelerating growth rate exhibited
Ashgate Publishing, March 2010, Pages: 500
approaches or about the best ways to pursue them. Consequently, control and prevention policies are mostly driven by political considerations, economic realities and cultural expectations, though research has
VDM Publishing House, Sep 2009, Pages: 136
With the rampant onslaught of HIV/AIDS pandemic, concern from various sectors of South Africa has led to the disease receiving much publicity in more than one way. Despite the vast amount
Global Industry Analysts, Inc., Aug 2010, Pages: 225
on Environment II-15
Condoms Fast Becoming a Way of Life II-15
Trends in New Product Development II-16
Decision Resources, Inc., Sep 2009, Pages: 36
and creating a more viable way of doing business are serious concerns. Many biotech companies have put themselves on ice with skeleton staffs in an attempt to ride out the recession, but they may never recover
Global Industry Analysts, Inc., Aug 2010, Pages: 571
, Funnels, Measuring Cylinders, Pipette and Pipette Tips, Racks, Tanks, Test Tubes, Tubings, and Vials).
The specific end-use segments discussed are Biotech/Life Science Research, Chemical/Petrochemical
Euromed Communications Ltd, Jan 2004
The Compendium places an important resource in your department or library. Because every quality of life study is unique, instruments were chosen to reflect varying user requirements. In this way
Global Industry Analysts, Inc., Sep 2011, Pages: 794
5
Companion Diagnostics: Leading the Way to Personalized Medicine 5
Table 1: Number of Companion Diagnostic Tests by Disease
Area: 2004-2008 (includes corresponding Graph
VDM Publishing House, Feb 2010, Pages: 236
In the last few decades, human life has been threatened by the sequential emergence of a number of unknown infectious and non-treatable diseases, such as human immunodeficiency virus (HIV), severe
RNCOS E-Services Private Limited, Jan 2012, Pages: 75
research institutions as well as small biotech and major pharmaceutical companies are increasingly looking for alternative ways to strengthen their pipelines.
The research reveals that personalized medicines for cancer
